Sandy Cove Advisors’s DexCom DXCM Stock Holding History

Sandy Cove Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-452	Closed	-$58K	–	158
2022 Q1	$58K	Sell	452 -24	-5%	-$2.63K	0.05%	178
2021 Q4	$64K	Buy	+476	New	+$68.4K	0.05%	164

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sandy Cove Advisors's DXCM Position: Q2 2022 in Review

Sandy Cove Advisors sold out of DexCom (DXCM) in Q2 2022, closing a stake of 452 shares — an estimated $58K sold.

Sandy Cove Advisors first reported a position in DXCM in Q4 2021 and held it in 2 quarters. The position peaked at $64K in Q4 2021. 797 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

Sandy Cove Advisors reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
Sandy Cove Advisors sold 452 DexCom shares in Q2 2022, an estimated $58K.
Sandy Cove Advisors first reported a position in DexCom in Q4 2021 and held it in 2 quarters.
Sandy Cove Advisors's DexCom position peaked at $64K in Q4 2021.
797 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Sandy Cove Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.